KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Non-Current Assets (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Non-Current Assets for 6 consecutive years, with $661.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets fell 9.95% year-over-year to $661.3 million, compared with a TTM value of $2.8 billion through Dec 2025, up 91.35%, and an annual FY2025 reading of $661.3 million, down 9.95% over the prior year.
  • Non-Current Assets was $661.3 million for Q4 2025 at Recursion Pharmaceuticals, down from $685.4 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $734.3 million in Q4 2024 and bottomed at $50.1 million in Q1 2021.
  • Average Non-Current Assets over 5 years is $289.1 million, with a median of $214.9 million recorded in 2023.
  • The sharpest move saw Non-Current Assets surged 240.66% in 2024, then dropped 9.95% in 2025.
  • Year by year, Non-Current Assets stood at $75.6 million in 2021, then skyrocketed by 73.85% to $131.5 million in 2022, then soared by 63.96% to $215.6 million in 2023, then soared by 240.66% to $734.3 million in 2024, then decreased by 9.95% to $661.3 million in 2025.
  • Business Quant data shows Non-Current Assets for RXRX at $661.3 million in Q4 2025, $685.4 million in Q3 2025, and $715.2 million in Q2 2025.